Physician

Alaeddin Ali Maeza

According to 2025 Medicare claims, Alaeddin Maeza (NPI: 1386937167) practices hematology/oncology in the Rockford, IL market, with the plurality of this provider's patient population coming from Winnebago, IL. This provider's primary affiliated billing organization is SWEDISHAMERICAN HOSPITAL (NPI: 1962451732; TIN: 362222696) and primary practice location at 61114-6624.

Maeza's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 337 traditional Medicare patients, billed 1,557 HCPCS/CPT codes, and received $75,078 in Medicare payments. The top billing code was 99222 (Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes). Part D data shows 1,873 prescription claims across 314 beneficiaries totaling $2,514,578 in drug costs, led by Abiraterone Acetate (Abiraterone Acetate). 2020 DME data shows 80 claims. Open Payments data shows 1 records totaling $20. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved sharply higher in recent years, from $16,145 to $75,078. Similarly, Part D prescription costs have risen steadily, from $192 to $2,514,578. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	104	225	$16,145
2016	42	59	$4,226
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	88	213	$12,840
2020	216	776	$38,918
2021	243	753	$44,402
2022	263	781	$48,248
2023	312	1,012	$72,845
2024	337	1,557	$75,078

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	N/R	11	$192
2016	20	52	$1,092
2017	N/R	N/R	N/R
2018	12	56	$63,248
2019	48	179	$45,714
2020	136	804	$889,134
2021	179	1,137	$1,677,608
2022	254	1,605	$1,557,182
2023	294	2,139	$2,526,845
2024	314	1,873	$2,514,578

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	80	$73,467
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	31	33	$97
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	158	560	$72
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	27	55	$58
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	127	180	$43
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	218	558	$12

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Abiraterone Acetate	Abiraterone Acetate	55	1,650	$285,196
Lenalidomide	Lenalidomide	31	819	$255,429
Xalkori	Crizotinib	12	360	$251,098
Ibrance	Palbociclib	12	336	$190,413
Xtandi	Enzalutamide	11	330	$150,521

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$20	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Alaeddin Ali Maeza?

Tedicare shows public-source Medicare data for Alaeddin Ali Maeza (NPI 1386937167), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Alaeddin Ali Maeza have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Alaeddin Ali Maeza?

Alaeddin Ali Maeza is linked to SWEDISHAMERICAN HOSPITAL (billing NPI 1962451732) in the available physician profile data.

Does Alaeddin Ali Maeza have Open Payments data?

Alaeddin Ali Maeza has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.